Case number 1:22-cv-01196
BioDelivery Sciences International, Inc. et al v. Chemo Research, S.L. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Feb 23, 2023 | 24 | SO ORDERED, re (23 in 1:22-cv-01196-CFC, 515 in 1:19-cv-00444-CFC-CJB) STIPULATION TO EXTEND TIME to file a redacted version of the Joint Status Report (D.I. 508 in 19-444-CFC, D.I. 17 in 22-1196-CFC) to February 24, 2023, filed by Insud Pharma S.L.U., IntelGenx Corp., IntelGenX Technologies Corp., Xiromed, LLC, Chemo Research, S.L., Insud Pharma S.L., IntelGenx Technologies Corp. Signed by Judge Colm F. Connolly on 2/23/2023. Associated Cases: 1:19-cv-00444-CFC-CJB, 1:22-cv-01196-CFC(kmd) (Entered: 02/23/2023) (3) |
| Feb 23, 2023 | 25 | REDACTED VERSION of (17 in 1:22-cv-01196-CFC, 508 in 1:19-cv-00444-CFC-CJB) Letter by Arius Two, Inc., BioDelivery Sciences International, Inc.. (Attachments: # 1 Exs. 1-9)(Tigan, Jeremy) (Entered: 02/23/2023) (Main Document) (4) |
| Feb 23, 2023 | 25 | REDACTED VERSION of (17 in 1:22-cv-01196-CFC, 508 in 1:19-cv-00444-CFC-CJB) Letter by Arius Two, Inc., BioDelivery Sciences International, Inc.. (Attachments: # 1 Exs. 1-9)(Tigan, Jeremy) (Entered: 02/23/2023) (Exs. 1-9) (30) |
| Feb 22, 2023 | 23 | STIPULATION TO EXTEND TIME to file a redacted version of the Joint Status Report (D.I. 508 in 19-444-CFC, D.I. 17 in 22-1196-CFC) to February 24, 2023 - filed by Chemo Research, S.L., Insud Pharma S.L.U., IntelGenx Corp., IntelGenx Technologies Corp., Xiromed, LLC, Insud Pharma S.L.. (Wilson, Samantha) (Entered: 02/22/2023) (3) |
| Feb 17, 2023 | 22 | STIPULATION TO EXTEND TIME to file a redacted version of the Joint Status Report (D.I. 508 in 19-444-CFC, D.I. 17 in 22-1196-CFC) to February 22, 2023 - filed by Arius Two, Inc., BioDelivery Sciences International, Inc.. (Tigan, Jeremy) (Entered: 02/17/2023) (2) |
| Feb 14, 2023 | 21 | STIPULATION TO EXTEND TIME to file a redacted version of the Joint Status Report (D.I. 508 in 19-444-CFC, D.I. 17 in 22-1196-CFC to February 17, 2023 - filed by Chemo Research, S.L., Insud Pharma S.L.U., IntelGenx Corp., IntelGenx Technologies Corp., Xiromed, LLC, Insud Pharma S.L.. (Wilson, Samantha) (Entered: 02/14/2023) (2) |
| Feb 10, 2023 | 20 | STIPULATION TO EXTEND TIME to file a redacted version of the Joint Status Report (D.I. 508 in 19-444-CFC, D.I. 17 in 22-1196-CFC) to February 14, 2023 - filed by Arius Two, Inc., BioDelivery Sciences International, Inc.. (Tigan, Jeremy) (Entered: 02/10/2023) (2) |
| Feb 9, 2023 | 19 | SO ORDERED, re (510 in 1:19-cv-00444-CFC-CJB) (18 in 1:22-cv-01196-CFC) STIPULATION TO EXTEND TIME to file a redacted version of the Joint Status Report (D.I 508 in 1:19-cv-00444-CFC-CJB) (D.I. 17 in 1:22-cv-01196-CFC) filed by IntelGenx Corp., IntelGenX Technologies Corp., Chemo Research, S.L., Insud Pharma S.L., Xiromed, LLC. Signed by Judge Colm F. Connolly on 2/9/2023. Associated Cases: 1:19-cv-00444-CFC-CJB, 1:22-cv-01196-CFC(kmd) (Entered: 02/09/2023) (2) |
| Feb 8, 2023 | 18 | STIPULATION TO EXTEND TIME to file a redacted version of the Joint Status Report (D.I. 17) to February 10, 2023 - filed by Chemo Research, S.L., Insud Pharma S.L.U., IntelGenx Corp., IntelGenx Technologies Corp., Xiromed, LLC. (Wilson, Samantha) (Main Document 18 replaced on 2/9/2023) (kmd). (Entered: 02/08/2023) (2) |
| Feb 1, 2023 | 17 | [SEALED] Joint Letter to The Honorable Colm F. Connolly from Jeremy A. Tigan regarding Status Report - re Oral Order,, Set Deadlines, Oral Order,, Status Report Order,. (Attachments: # 1 Exhibits 1-9)(Tigan, Jeremy) (Entered: 02/01/2023) (0) |
| Jan 6, 2023 | 16 | Joint Letter to The Honorable Colm F. Connolly from Jeremy A. Tigan regarding the Rule 16 Scheduling Conference set for January 13, 2023 - re 15 Order Setting Scheduling Conference,. (Tigan, Jeremy) (Entered: 01/06/2023) (1) |
| Dec 12, 2022 | 15 | Order Setting Telephonic Scheduling Conference: A Scheduling Conference is set for 1/13/2023 at 11:30 AM before Judge Colm F. Connolly. If the parties have no disputes about the scheduling order, the Court will not require the parties to appear at a conference. Signed by Judge Colm F. Connolly on 12/12/2022. (nmf) (Entered: 12/12/2022) (2) |
| Dec 1, 2022 | 14 | ANSWER to 8 Answer to Complaint, Counterclaim by Arius Two, Inc., BioDelivery Sciences International, Inc..(Tigan, Jeremy) (Entered: 12/01/2022) (17) |
| Nov 11, 2022 | 13 | NOTICE OF SERVICE of Defendants/Counterclaim Plaintiffs' Production of Abbreviated New Drug Application No. 212036 filed by Chemo Research, S.L., Insud Pharma S.L.U., IntelGenx Corp., IntelGenx Technologies Corp., Xiromed, LLC.(Wilson, Samantha) (Entered: 11/11/2022) (3) |
| Nov 10, 2022 | 8 | ANSWER to 1 Complaint, , COUNTERCLAIM against Arius Two, Inc., BioDelivery Sciences International, Inc. by Insud Pharma S.L.U., Xiromed, LLC, Chemo Research, S.L., IntelGenx Technologies Corp., IntelGenx Corp..(Gaza, Anne) (Entered: 11/10/2022) (30) |
| Nov 10, 2022 | 9 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Insud Pharma S.L.U. for Chemo Research, S.L. filed by Chemo Research, S.L.. (Gaza, Anne) (Entered: 11/10/2022) (4) |
| Nov 10, 2022 | 10 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Grupo Insud GmbH for Insud Pharma S.L.U. filed by Insud Pharma S.L.U.. (Gaza, Anne) (Entered: 11/10/2022) (4) |
| Nov 10, 2022 | 11 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent IntelGenX Technologies Corp. for IntelGenx Corp.; Other Affiliate atai Life Sciences N.V. for IntelGenx Technologies Corp. filed by IntelGenx Corp., IntelGenx Technologies Corp.. (Gaza, Anne) (Entered: 11/10/2022) (4) |
| Nov 10, 2022 | 12 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Xiromed, LLC. (Gaza, Anne) (Entered: 11/10/2022) (4) |
| Oct 20, 2022 | 7 | WAIVER OF SERVICE returned executed by BioDelivery Sciences International, Inc., Arius Two, Inc.: For Chemo Research, S.L. waiver sent on 9/27/2022, answer due 11/28/2022; Insud Pharma S.L.U. waiver sent on 9/27/2022, answer due 11/28/2022; IntelGenx Corp. waiver sent on 9/27/2022, answer due 11/28/2022; IntelGenx Technologies Corp. waiver sent on 9/27/2022, answer due 11/28/2022; Xiromed, LLC waiver sent on 9/27/2022, answer due 11/28/2022. (Tigan, Jeremy) (Entered: 10/20/2022) (5) |
| Sep 12, 2022 | 1 | Complaint* (1) |
| Sep 12, 2022 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (apk) (Entered: 09/13/2022) (3) |
| Sep 12, 2022 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 8/1/2022. Date of Expiration of Patent: SEE ANDA FORM.Thirty Month Stay Deadline: 2/1/2025. (apk) (Entered: 09/13/2022) (1) |
| Sep 12, 2022 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,147,866 B2 ;9,655,843 B2 ;9,901,539 B2. (apk) (Entered: 09/13/2022) (1) |
| Sep 12, 2022 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Collegium Pharmaceutical, Inc. for BioDelivery Sciences International, Inc.; Corporate Parent BioDelivery Sciences International, Inc. for Arius Two, Inc. filed by Arius Two, Inc., BioDelivery Sciences International, Inc. (apk) (Entered: 09/13/2022) (1) |
| Sep 12, 2022 | 6 | Summonses Issued (please complete the top portion of the form and print out for use/service). (apk) (Entered: 09/13/2022) (2) |
